Medigene Ag

Universitaet Zu Koeln

Ludwig-maximilians-universitaet

Deutsches Krebsforschungszentrum

Kerstin Lux

Markus Hoerer

Michael Hallek

Luca Perabo

Jürgen Kleinschmidt

John Nieland

Hildegard Buening

Mirko Ritter

Jorge Boucas

Juergen Kleinschmidt

Florian Sonntag

Daniela Goldnau

Markus HÖRER

Daniela KÜHN

Hildegard BÜNING

The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.

Mutated structural protein of a parvovirus

The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.

The present invention relates to nucleic acids encoding the novel parvoviral protein 'assembly activating protein' (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3. Furthermore, the invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use.

Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3

Growing community of inventors

Munich, Germany

Kerstin Lux